Related references
Note: Only part of the references are listed.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Sharon Amit et al.
LANCET (2021)
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Eleftheria Vasileiou et al.
LANCET (2021)
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Jamie Lopez Bernal et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
Nawal Al Kaabi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri et al.
LANCET INFECTIOUS DISEASES (2021)
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Emma Pritchard et al.
NATURE MEDICINE (2021)
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
Gabriel Chodick et al.
JAMA NETWORK OPEN (2021)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
Age-specific mortality and immunity patterns of SARS-CoV-2
Megan O'Driscoll et al.
NATURE (2020)